Circulating Monocytes Are Predictive and Responsive in Moderate-to-Severe Plaque Psoriasis Subjects Treated with Apremilast

• Published in: Journal of investigative dermatology Vol. 144; no. 9; pp. 1963 - 1974.e13
• Main Authors: Larson, Emma L., DeMeo, Dustin P., Young, Andrew B., Margevicius, Seunghee, Rutter, Joseph, Davies, Amanda L., Rohan, Craig A., Korman, Neil J., Travers, Jeffrey B., McCormick, Thomas S., Cooper, Kevin D.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.09.2024
• Subjects: Adult; Anti-Inflammatory Agents, Non-Steroidal - pharmacology; Anti-Inflammatory Agents, Non-Steroidal - therapeutic use; Apremilast; Biomarker; Biomarkers - blood; Biomarkers - metabolism; Cell Adhesion - drug effects; Female; Flow Cytometry; Humans; Male; Middle Aged; Monocytes; Monocytes - drug effects; Monocytes - metabolism; Phosphodiesterase 4 Inhibitors - pharmacology; Phosphodiesterase 4 Inhibitors - therapeutic use; Psoriasis; Psoriasis - drug therapy; Severity of Illness Index; Thalidomide - analogs & derivatives; Thalidomide - pharmacology; Thalidomide - therapeutic use; Transcriptome; Treatment Outcome; DLQI; Biomarker; Monocytes; Psoriasis; PDE4; Transcriptome; DEG; Apremilast; MPA

Monocytes play a critical role in the inflammation associated with psoriasis, and their abnormalities have been reported as biomarkers of cardiovascular event risk, a psoriasis comorbidity. Monocytic cells in chronic inflammatory disorders express elevated levels of cAMP phosphodiesterase. Restoring...